Using the light, LuViva scans the cervix and identifies cancer and pre-cancer painlessly and non-invasively.
LuViva utilizes the company’s patented biophotonic technology and detects changes at the cellular level, thus helps in distinguishing between normal and diseased tissue.
Guided Therapeutics CEO and president Mark Faupel said they believe that LuViva has the potential to bring a new level of efficiency to women’s healthcare in Canada and improve the standard of care by providing immediate results with a painless, one-minute test.
"Additionally, the Health Canada approval helps to jumpstart and support the regulatory process in some Latin America and Southeast Asian countries," Faupel added.
